Showing 1961-1970 of 5610 results for "".
Predicting the Development of Food Allergies with Skin Biomarkers
https://reachmd.com/programs/frontlines-food-allergies/predicting-the-development-of-food-allergies-with-skin-biomarkers/18015/Tune in to find out how skin biomarkers can predict the development of food allergies based on findings from a recent study.Investigating the Latest Innovations in IBD
https://reachmd.com/programs/gi-insights/investigating-the-latest-innovations-in-ibd/13471/From new diagnostic tools to novel therapies, find out how IBD care and management have evolved.Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
https://reachmd.com/programs/cme/contrasting-trop2-targeted-adcs-in-breast-cancer-therapy/33024/Compare TROP2-targeted ADCs for mBC by molecular structure, patient eligibility, and clinical evidence to guide patient-centered treatment strategiesTau and Neurodegeneration in Alzheimer’s Disease: Bridging Pathology and Clinical Progression Through Biomarkers
https://reachmd.com/programs/medical-industry-feature/tau-neurodegeneration-alzheimers-biomarkers/37875/For the latest insights on tau and neurodegeneration biomarkers in Alzheimer’s disease (AD), tune in to this recorded presentation featuring Doctor Michelle Mielke and Professor Henrik Zetterberg. Together, they delve into the role of tau in AD, exploring the ‘tau cascade’, the current use of tau aAdvancing Care: Clinical Innovations on the Horizon
https://reachmd.com/programs/cme/advancing-care-clinical-innovations-on-the-horizon/35881/Learn about LGMD2I/R9—genetics, diagnosis, treatment, clinical trials, and care gaps—in this expert-led, comprehensive educational video series.CGM in the Real T2D World
https://reachmd.com/programs/cme/cgm-real-t2d-world/50982/Continuous glucose monitoring (CGM) is still recommended for all individuals with diabetes, including those with type 2 diabetes (T2D). Despite this, its use in managing T2D has not been as widespread as expected. New evidence has recently highlighted the benefits of CGM for people with T2D. Join ouStemming the Tide on MASLD/MASH: It Starts on the Frontlines in Endocrinology and Primary Care Clinics
https://reachmd.com/programs/cme/stemming-the-tide-on-masldmash-it-starts-on-the-frontlines-in-endocrinology-and-primary-care-clinics/35568/Join us for a broadcast replay from Global Fatty Liver Day to learn more about cardiometabolic risk factors and improve your care of patients with MASLD/MASH.Modern Management of ROS1-Positive Non-Small Cell Lung Cancer
https://reachmd.com/programs/project-oncology/modern-management-of-ros1-positive-non-small-cell-lung-cancer/54574/Chimeric Antigen Receptor T-Cell Therapy for Progressive Multiple Sclerosis: Rationale, Evidence, and Therapeutic Potential
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/chimeric-antigen-receptor-t-cell-therapy-for-progressive-multiple-sclerosis-rationale-evidence-and-therapeutic-potential/56914/CAR T-cell therapy represents a new strategy for treating progressive multiple sclerosis by targeting pathogenic B cells involved in compartmentalized neuroinflammation.Expanding Access to CAR T-Cell Therapy in R/R Myeloma Care
https://reachmd.com/programs/project-oncology/expanding-access-to-car-t-cell-therapy-in-rr-myeloma-care/48731/This is a non-certified educational series produced and controlled by ReachMD. While BCMA-directed CAR T-cell therapy has changed the treatment landscape for patients with relapsed and refractory (R/R) multiple myeloma, access remains uneven outside academic centers. In this expert-led discussion, D